Abstract

<div>Abstract<p>Background: Immune profiles have been associated with bladder cancer outcomes and may have clinical applications for prognosis. However, associations of detailed immune cell subtypes with patient outcomes remain underexplored and may contribute crucial prognostic information for better managing bladder cancer recurrence and survival. Methods: Bladder cancer case peripheral blood DNA methylation was measured using the Illumina HumanMethylationEPIC array. Extended cell-type deconvolution quantified twelve immune cell-type proportions, including memory, naïve T and B cells, and granulocyte subtypes. DNA methylation clocks determined biological age. Cox proportional hazard models tested associations of immune cell profiles and age acceleration with bladder cancer outcomes. The partDSA algorithm discriminated 10-year overall survival groups from clinical variables and immune cell profiles, and a semi-supervised recursively partitioned mixture model with DNA methylation data was applied to identify a classifier for 10-year overall survival. Results: Higher CD8T memory cell proportions were associated with better overall survival (HR=0.95, 95% CI=0.93-0.98), while higher NLR (HR=1.36, 95% CI=1.23-1.50), CD8T naïve (HR=1.21, 95% CI=1.04-1.41), neutrophil (HR=1.04, 95% CI=1.03-1.06) proportions, and age acceleration (HR =1.06, 95% CI=1.03-1.08) were associated with worse overall survival in bladder cancer patients. partDSA and SS-RPMM classified five groups of subjects with significant differences in overall survival. Conclusions: We identified associations between immune cell subtypes and age acceleration with bladder cancer outcomes. Impact: The findings of this study suggest that bladder cancer outcomes are associated with specific methylation-derived immune cell-type proportions and age acceleration, and these factors could be potential prognostic biomarkers.</p></div>

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.